Test Price
2,800 AED✅ Home Collection Available
MYO15A Gene Deafness, Autosomal Recessive Type 3 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 and 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation by DHA-Licensed Genetic Counselor.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731. We accept all major UAE medical insurers.
Test Overview & Methodology
The MYO15A gene sequencing test detects pathogenic variants linked to autosomal recessive deafness type 3 (DFNB3), a congenital or prelingual severe-to-profound sensorineural hearing loss. This NGS-based analysis provides definitive molecular diagnosis, guides cochlear implantation candidacy, and supports familial recurrence risk assessment.
Comparison: Targeted MYO15A NGS vs. Whole Exome Sequencing
| Feature | Our Test (MYO15A NGS) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision (Coverage) | >99% CDS coverage at 50× depth, specific to MYO15A | Variable; many genes sequenced but with lower target coverage |
| Methodology | Targeted NGS with Sanger confirmation of all variants | Whole Exome Sequencing (WES) plus Sanger validation |
| Turnaround Time | 3–4 Weeks | 8–12 Weeks |
| Clinical Utility | Gold standard for DFNB3 confirmation and carrier testing | Broader search for unknown aetiologies; higher incidental findings rate |
Physician Insight & Safety Protocols
“A positive MYO15A result confirms hereditary deafness with implications for auditory habilitation and family planning. However, genetic data must be correlated with audiological phenotype and family history. A negative report does not exclude other genetic or environmental causes of hearing loss, and clinical follow-up remains essential.”
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Reg ID: 9294403
Medication Advisory
⚠ Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. This genetic test is a diagnostic tool and does not directly determine drug regimens.
Safety Exclusions & Red Flags
- Not indicated for sudden sensorineural hearing loss (SSNHL) with acute onset; seek emergency ENT care.
- Unsuitable if patient lacks a clinical phenotype or family history consistent with DFNB3.
- Do not substitute for newborn hearing screening; it complements physiological tests.
- Red Flag Symptoms: Acute vertigo, unilateral tinnitus, otalgia, or facial nerve palsy require urgent otological evaluation, not elective genetic testing.
Patient FAQ & Clinical Guidance
1. What is the purpose of the MYO15A gene test?
This genetic test identifies mutations in the MYO15A gene responsible for autosomal recessive deafness type 3, enabling precise diagnosis, cochlear implant prognosis, and familial counseling.
2. How is the test performed and what is the sample requirement?
The test requires a simple blood sample, extracted DNA, or a single drop of blood on an FTA card, all collected via our VIP home phlebotomy service.
3. What is the turnaround time and how will I receive the results?
Results are delivered in 3–4 weeks via a secure, DHA-compliant electronic report with genetic counseling support included.
UAE Regulatory & Data Privacy Adherence
Our laboratory operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic data is handled with strict confidentiality and ethical safeguards. The facility is licensed by the Dubai Health Authority (DHA License No. 1143) and holds ISO 9001:2015 certification.
Clinical & Logistical Metadata
| Test Name | MYO15A Gene Sequencing for Autosomal Recessive Deafness Type 3 (DFNB3) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily from 8 AM to 11 PM |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 81304-5 |
| DHA Facility License & Laboratory Address | DHA License: 1143, DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians